432 related articles for article (PubMed ID: 34962574)
41. The inhibition of catechol O-methyltransferase and monoamine oxidase by tetralone and indanone derivatives substituted with the nitrocatechol moiety.
de Beer AD; Legoabe LJ; Petzer A; Petzer JP
Bioorg Chem; 2021 Sep; 114():105130. PubMed ID: 34225162
[TBL] [Abstract][Full Text] [Related]
42. Current pharmacotherapeutic treatment options in Parkinson's disease.
Rezak M
Dis Mon; 2007 Apr; 53(4):214-22. PubMed ID: 17586328
[TBL] [Abstract][Full Text] [Related]
43. Real life evaluation of safinamide effectiveness in Parkinson's disease.
Mancini F; Di Fonzo A; Lazzeri G; Borellini L; Silani V; Lacerenza M; Comi C
Neurol Sci; 2018 Apr; 39(4):733-739. PubMed ID: 29441484
[TBL] [Abstract][Full Text] [Related]
44. Advanced strategies for treatment of Parkinson's disease: the role of early treatment.
Jann MW
Am J Manag Care; 2011 Oct; 17 Suppl 12():S315-21. PubMed ID: 22087552
[TBL] [Abstract][Full Text] [Related]
45. [Medical treatment of Parkinson's disease in elderly and multimorbid patients].
Lettow I; Röther J
Internist (Berl); 2014 Jun; 55(6):728-34. PubMed ID: 24806271
[TBL] [Abstract][Full Text] [Related]
46. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E;
Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996
[TBL] [Abstract][Full Text] [Related]
47. Parkinson's disease--levodopa complications.
King DB
Can J Neurol Sci; 1999 Aug; 26 Suppl 2():S13-20. PubMed ID: 10451755
[TBL] [Abstract][Full Text] [Related]
48. The therapeutic potential of moclobemide, a reversible selective monoamine oxidase A inhibitor in Parkinson's disease.
Sieradzan K; Channon S; Ramponi C; Stern GM; Lees AJ; Youdim MB
J Clin Psychopharmacol; 1995 Aug; 15(4 Suppl 2):51S-59S. PubMed ID: 7593732
[TBL] [Abstract][Full Text] [Related]
49. [A prospect of treatment for Parkinson's disease in the 21st century].
Yanagisawa N
Nihon Rinsho; 2000 Oct; 58(10):1968-74. PubMed ID: 11068433
[TBL] [Abstract][Full Text] [Related]
50. Pharmacotherapy for Parkinson's disease.
Chen JJ; Swope DM
Pharmacotherapy; 2007 Dec; 27(12 Pt 2):161S-173S. PubMed ID: 18041936
[TBL] [Abstract][Full Text] [Related]
51. Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study.
Ries V; Selzer R; Eichhorn T; Oertel WH; Eggert K;
Clin Neuropharmacol; 2010 May; 33(3):142-50. PubMed ID: 20502133
[TBL] [Abstract][Full Text] [Related]
52. [Enzyme inhibitors in Parkinson treatment].
Gütschow M; Meusel M
Pharm Unserer Zeit; 2006; 35(3):218-25. PubMed ID: 16724525
[No Abstract] [Full Text] [Related]
53. [The role of selective monoamine oxidase B inhibitors in the therapeutic strategy of Parkinson's disease in the neurology clinics of Tirgu Mures County Emergency Clinical Hospital].
Szász JA; Constantin V; Fazakas PA; Blényesi E; Grieb LG; Balla A; Sárig M; Szegedi K; Bartha EN; Szatmári S
Orv Hetil; 2017 Dec; 158(51):2023-2028. PubMed ID: 29250969
[TBL] [Abstract][Full Text] [Related]
54. Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.
Najib J
Clin Ther; 2001 Jun; 23(6):802-32; discussion 771. PubMed ID: 11440283
[TBL] [Abstract][Full Text] [Related]
55. Monoamine Oxidase B Inhibitors in Parkinson's Disease.
Dezsi L; Vecsei L
CNS Neurol Disord Drug Targets; 2017; 16(4):425-439. PubMed ID: 28124620
[TBL] [Abstract][Full Text] [Related]
56. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
57. Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.
Lees AJ; Ferreira J; Rascol O; Poewe W; Rocha JF; McCrory M; Soares-da-Silva P;
JAMA Neurol; 2017 Feb; 74(2):197-206. PubMed ID: 28027332
[TBL] [Abstract][Full Text] [Related]
58. The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease.
Chong DJ; Suchowersky O; Szumlanski C; Weinshilboum RM; Brant R; Campbell NR
Clin Neuropharmacol; 2000; 23(3):143-8. PubMed ID: 10895397
[TBL] [Abstract][Full Text] [Related]
59. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.
Deleu D; Northway MG; Hanssens Y
Clin Pharmacokinet; 2002; 41(4):261-309. PubMed ID: 11978145
[TBL] [Abstract][Full Text] [Related]
60. Advances in the pharmacologic management of early Parkinson disease.
Hauser RA; Zesiewicz TA
Neurologist; 2007 May; 13(3):126-32. PubMed ID: 17495756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
